Literature DB >> 25192681

Rare metastases of well-differentiated thyroid cancers: a systematic review.

Amin Madani1, Yelda Jozaghi, Roger Tabah, Jacques How, Elliot Mitmaker.   

Abstract

BACKGROUND: A minority of metastatic well-differentiated thyroid cancer (WDTC) patients present with end-organ disease other than in the lung, bone or lymph nodes. These metastases tend to be overlooked because of their low incidence, and this results in delayed diagnosis. The purpose of this study was to perform a systematic review of the clinical and histologic features of unusual WDTC metastases.
METHODS: A systematic literature search of bibliographic databases, reference lists of articles, and conference proceedings was performed up to 2013. Studies were included if they reported on adult patients with WDTC and pathology-proven metastases to end-organs other than lung, bone, or lymph nodes. A total of 238 studies were included in a qualitative analysis. Data is expressed as N (%) and median [interquartile range].
RESULTS: A total of 492 patients (median age, 62 years [50-70 years]) were identified in 197 case reports and 42 case series. There were 22 different end-organ metastatic sites documented with either papillary [255 (57 %)], follicular [172 (39 %)], or Hürthle-cell [18 (4 %)] histology. A total of 181 (41 %) patients presented with solitary metastasis and 54 (93 %) with elevated serum thyroglobulin. Positron emission tomography and whole-body radioactive iodine scans revealed hypermetabolic foci in 28 (97 %) and 50 (81 %) cases, respectively. Disease-free interval following the initial diagnosis of the primary thyroid cancer was highly variable, ranging from synchronous presentation [66 (33 %)] to metachronous disease after 516 months [mean 86 months (SD 90)].
CONCLUSIONS: WDTC can manifest with highly variable and unusual clinical features. Rare sites of metastases should be considered in the absence of the more common extra-cervical disease recurrence locations.

Entities:  

Mesh:

Year:  2014        PMID: 25192681     DOI: 10.1245/s10434-014-4058-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

1.  Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway.

Authors:  Baiyu Han; Hanzhi Cui; Lei Kang; Xuelin Zhang; Zhitao Jin; Lanmin Lu; Zhongyi Fan
Journal:  Tumour Biol       Date:  2015-04-09

2.  Bilateral Renal Metastasis of Hürthle Cell Thyroid Cancer with Discordant Uptake Between I-131 Sodium Iodide and F-18 FDG.

Authors:  Apichaya Claimon; Minseok Suh; Gi Jeong Cheon; Dong Soo Lee; E Edmund Kim; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2016-12-09

3.  Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases.

Authors:  Anabela Zunino; Fabián Pitoia; Eduardo Faure; Adriana Reyes; Mónica Sala; Rosana Sklate; Verónica Ilera; Inés Califano
Journal:  Endocrine       Date:  2019-07-20       Impact factor: 3.633

4.  Cardiac metastasis of squamous cell carcinoma of the thyroid gland with severe disseminated intravascular coagulation: A case report.

Authors:  Tomoyasu Yoshihiro; Kenji Tsuchihashi; Hitoshi Kusaba; Torahiko Nakashima; Teppei Obara; Kenta Nio; Kotoe Takayoshi; Hiroyuki Kodama; Nobuhiro Tsuruta; Hideyuki Kiyohara; Kaori Asai; Eiji Harada; Kenjiro Kamezaki; Takeshi Arita; Masanobu Sato; Hidetaka Yamamoto; Shuji Arita; Hiroshi Ariyama; Keita Odashiro; Yoshinao Oda; Koichi Akashi; Eishi Baba
Journal:  Mol Clin Oncol       Date:  2016-11-23

5.  Clinical Status and Treatment of Liver Metastasis of Differentiated Thyroid Cancer Using Tyrosine Kinase Inhibitors.

Authors:  Yoshiyuki Saito; Kiminori Sugino; Hiroshi Takami; Kenichi Matsuzu; Takashi Uruno; Keiko Ohkuwa; Wataru Kitagawa; Mitsuji Nagahama; Hirofumi Kawakubo; Koichi Ito; Yuko Kitagawa
Journal:  World J Surg       Date:  2018-11       Impact factor: 3.352

Review 6.  Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review.

Authors:  Eleonora Farina; Fabio Monari; Giovanni Tallini; Andrea Repaci; Renzo Mazzarotto; Francesca Giunchi; Riccardo Panzacchi; Silvia Cammelli; Gilbert D A Padula; Francesco Deodato; Renato Pasquali; Stefano Fanti; Michelangelo Fiorentino; Alessio G Morganti
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

7.  Clinical outcomes of a cohort of patients with central nervous system metastases from thyroid cancer.

Authors:  Joana Simões-Pereira; Daniel Macedo; Maria João Bugalho
Journal:  Endocr Connect       Date:  2016-11-17       Impact factor: 3.335

Review 8.  Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.

Authors:  Naoki Fukuda; Shunji Takahashi
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

9.  Hypoxia Increases Thyroid Cancer Stem Cell-Enriched Side Population.

Authors:  K Mahkamova; N Latar; S Aspinall; A Meeson
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

10.  Unusual Presentation of Differentiated Thyroid Cancer Metastasis.

Authors:  Haissan Iftikhar; Mubasher Ikram; Adnan Yar Muhammad; Karim Rizwan Nathani
Journal:  Int Arch Otorhinolaryngol       Date:  2017-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.